SorLA in Interleukin-6 Signaling and Turnover

被引:16
|
作者
Larsen, Jakob Vejby [1 ]
Petersen, Claus Munck [1 ]
机构
[1] Aarhus Univ, Dept Biomed, MIND Ctr, Aarhus, Denmark
关键词
IL-6; IL-6R; STAT3; signaling; SorLA; Vps10p domain receptors; cytokines; endocytosis; AMYLOID PRECURSOR PROTEIN; RECEPTOR FAMILY-MEMBER; CILIARY NEUROTROPHIC FACTOR; LIGAND-INDUCED ENDOCYTOSIS; CIRCULATING SOLUBLE LR11; IL-6; RECEPTOR; CYTOPLASMIC DOMAIN; PROPEPTIDE CLEAVAGE; MONOCLONAL-ANTIBODY; DOWN-REGULATION;
D O I
10.1128/MCB.00641-16
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Interleukin-6 (IL-6) is a multifunctional cytokine with important functions in various physiologic processes. Mice lacking IL-6 exhibit multiple phenotypic abnormalities, such as an inadequate immune and acute-phase response, and elevated levels of circulating IL-6 have been found to accompany several pathological conditions. IL-6 binds the nonsignaling IL-6 receptor (IL-6R), which is expressed as a transmembrane, as well as a secreted circulating protein, before it engages homodimeric gp130 for signaling. Complex formation between IL-6 and the membrane-bound IL-6 receptor gives rise to classic cis signaling, whereas complex formation between IL-6 and the soluble IL-6R results in trans signaling. Here, we report that the endocytic receptor SorLA targets IL-6 and IL-6R. We present evidence that SorLA mediates efficient cellular uptake of both IL-6 and the circulating IL-6R in astrocytes. We further show that SorLA interacts with the membrane-bound IL-6R at the cell surface and thereby downregulates IL-6 cis signaling. Finally, we find that the SorLA ectodomain, released from the cell membrane upon enzymatic cleavage of full-length SorLA, may act as an IL-6 carrier protein that stabilizes IL-6 and its capacity for trans signaling.
引用
收藏
页数:18
相关论文
共 50 条
  • [1] NUCLEAR SIGNALING BY INTERLEUKIN-6
    CHENKIANG, S
    HSU, W
    NATKUNAM, Y
    ZHANG, XK
    CURRENT OPINION IN IMMUNOLOGY, 1993, 5 (01) : 124 - 128
  • [2] Interleukin-6 signaling in podocyte hypertrophy
    Cha, Dae Ryong
    KIDNEY RESEARCH AND CLINICAL PRACTICE, 2016, 35 (04) : 195 - 196
  • [3] Targeting Interleukin-6 Signaling in Clinic
    Kang, Sujin
    Tanaka, Toshio
    Narazaki, Masashi
    Kishimoto, Tadamitsu
    IMMUNITY, 2019, 50 (04) : 1007 - 1023
  • [4] Inhibition of interleukin-6 signaling by galiellalactone
    Weidler, M
    Rether, J
    Anke, T
    Erkel, G
    FEBS LETTERS, 2000, 484 (01) : 1 - 6
  • [5] Interleukin-6 is not essential for bone turnover in hypothyroid mice
    Mysliwiec, Janusz
    Zbucki, Robert
    Winnicka, Maria M.
    Sawicki, Boguslaw
    Nikolajuk, Agnieszka
    Kaminski, Karol
    Mysliwiec, Piotr
    Musial, Wlodzimierz
    Bondyra, Zofia
    Walecki, Jerzy
    Gorska, Maria
    FOLIA HISTOCHEMICA ET CYTOBIOLOGICA, 2007, 45 (04) : 387 - 392
  • [6] INTRACELLULAR RETENTION OF INTERLEUKIN-6 ABROGATES SIGNALING
    ROSEJOHN, S
    SCHOOLTINK, H
    SCHMITZVANDELEUR, H
    MULLBERG, J
    HEINRICH, PC
    GRAEVE, L
    JOURNAL OF BIOLOGICAL CHEMISTRY, 1993, 268 (29) : 22084 - 22091
  • [7] The role of interleukin-6 signaling in nervous tissue
    Rothaug, Michelle
    Becker-Pauly, Christoph
    Rose-John, Stefan
    BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH, 2016, 1863 (06): : 1218 - 1227
  • [8] The Good, the Bad, and the Ugly of interleukin-6 signaling
    Fuster, Jose J.
    Walsh, Kenneth
    EMBO JOURNAL, 2014, 33 (13): : 1425 - 1427
  • [9] Interleukin-6: Biology, signaling and strategies of blockade
    Schaper, Fred
    Rose-John, Stefan
    CYTOKINE & GROWTH FACTOR REVIEWS, 2015, 26 (05) : 475 - 487
  • [10] Interleukin-6 Signaling and Anti-Interleukin-6 Therapeutics in Cardiovascular Disease
    Ridker, Paul M.
    Rane, Manas
    CIRCULATION RESEARCH, 2021, 128 (11) : 1728 - 1746